We are on a global mission to establish gene therapy as a new standard of care for highly prevalent ocular diseases.
Gene Therapy β’ Biotechnology β’ Rare Diseases β’ Ophthalmology β’ Retina
51 - 200
π° $217M Post-IPO Equity on 2020-08
April 13
51 - 200
πΊπΈ United States β Remote
π° $217M Post-IPO Equity on 2020-08
β° Full Time
π Senior
π Data Scientist
π½ H1B Visa Sponsor